JP2018535701A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535701A5 JP2018535701A5 JP2018546725A JP2018546725A JP2018535701A5 JP 2018535701 A5 JP2018535701 A5 JP 2018535701A5 JP 2018546725 A JP2018546725 A JP 2018546725A JP 2018546725 A JP2018546725 A JP 2018546725A JP 2018535701 A5 JP2018535701 A5 JP 2018535701A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- item
- antigen
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 100
- 239000000427 antigen Substances 0.000 claims description 54
- 102000036639 antigens Human genes 0.000 claims description 54
- 108091007433 antigens Proteins 0.000 claims description 54
- 230000000890 antigenic effect Effects 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 32
- 108091008874 T cell receptors Proteins 0.000 claims description 31
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 31
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 210000000130 stem cell Anatomy 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 108020003175 receptors Proteins 0.000 claims description 23
- 102000005962 receptors Human genes 0.000 claims description 23
- 230000003213 activating effect Effects 0.000 claims description 15
- 230000011664 signaling Effects 0.000 claims description 14
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 12
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 12
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- -1 for example Proteins 0.000 claims description 11
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 8
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 8
- 102000054766 genetic haplotypes Human genes 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 5
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 4
- 238000006471 dimerization reaction Methods 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 101150047061 tag-72 gene Proteins 0.000 claims description 4
- 230000006044 T cell activation Effects 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 13
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 7
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 4
- 108700010039 chimeric receptor Proteins 0.000 description 4
- 230000004068 intracellular signaling Effects 0.000 description 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 101710185679 CD276 antigen Proteins 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 102100037904 CD9 antigen Human genes 0.000 description 2
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 2
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012737 microarray-based gene expression Methods 0.000 description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021183110A JP2022027762A (ja) | 2015-11-27 | 2021-11-10 | 遺伝子改変された細胞およびその使用 |
| JP2024010098A JP2024028648A (ja) | 2015-11-27 | 2024-01-26 | 遺伝子改変された細胞およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015904933 | 2015-11-27 | ||
| AU2015904933A AU2015904933A0 (en) | 2015-11-27 | Genetically modified cells and uses thereof | |
| AU2016901328 | 2016-04-11 | ||
| AU2016901328A AU2016901328A0 (en) | 2016-04-11 | Genetically modified cells and uses thereof - III | |
| PCT/AU2016/051141 WO2017088012A1 (en) | 2015-11-27 | 2016-11-23 | Genetically modified cells and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021183110A Division JP2022027762A (ja) | 2015-11-27 | 2021-11-10 | 遺伝子改変された細胞およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535701A JP2018535701A (ja) | 2018-12-06 |
| JP2018535701A5 true JP2018535701A5 (enExample) | 2019-12-26 |
| JP6976960B2 JP6976960B2 (ja) | 2021-12-08 |
Family
ID=58762790
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546725A Active JP6976960B2 (ja) | 2015-11-27 | 2016-11-23 | 遺伝子改変された細胞およびその使用 |
| JP2021183110A Pending JP2022027762A (ja) | 2015-11-27 | 2021-11-10 | 遺伝子改変された細胞およびその使用 |
| JP2024010098A Pending JP2024028648A (ja) | 2015-11-27 | 2024-01-26 | 遺伝子改変された細胞およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021183110A Pending JP2022027762A (ja) | 2015-11-27 | 2021-11-10 | 遺伝子改変された細胞およびその使用 |
| JP2024010098A Pending JP2024028648A (ja) | 2015-11-27 | 2024-01-26 | 遺伝子改変された細胞およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11400145B2 (enExample) |
| EP (3) | EP3380117B1 (enExample) |
| JP (3) | JP6976960B2 (enExample) |
| CN (2) | CN116121281B (enExample) |
| AU (2) | AU2016361451B2 (enExample) |
| CA (1) | CA3004120A1 (enExample) |
| ES (2) | ES2988976T3 (enExample) |
| IL (2) | IL296410A (enExample) |
| MY (1) | MY189819A (enExample) |
| SG (2) | SG11201803493UA (enExample) |
| WO (1) | WO2017088012A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2978186A1 (en) | 2015-03-05 | 2016-09-09 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| US20200283534A1 (en) * | 2016-06-24 | 2020-09-10 | iCell Gene Therapeuticics LLC | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
| JP7193862B2 (ja) | 2016-08-03 | 2022-12-21 | ワシントン・ユニバーシティ | キメラ抗原受容体でのｔ細胞性悪性腫瘍の治療のためのｃａｒ－ｔ細胞の遺伝子編集 |
| EP3510145A4 (en) | 2016-09-06 | 2020-03-25 | The Children's Medical Center Corporation | IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS |
| JP2020511136A (ja) | 2017-03-17 | 2020-04-16 | フレッド ハッチンソン キャンサー リサーチ センター | 免疫調節性融合タンパク質およびその使用 |
| CA3058807A1 (en) | 2017-04-03 | 2018-10-11 | Neon Therapeutics, Inc. | Protein antigens and uses thereof |
| JP7181219B2 (ja) | 2017-04-18 | 2022-11-30 | フジフィルム セルラー ダイナミクス，インコーポレイテッド | 抗原特異的免疫エフェクター細胞 |
| IL273961B2 (en) | 2017-10-18 | 2025-04-01 | Precigen Inc | Polypeptide compositions containing spacers |
| TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| CN109971716B (zh) * | 2017-12-28 | 2023-08-01 | 上海细胞治疗研究院 | 自分泌cd47抗体的egfr特异性car-t细胞及其用途 |
| CN109971721B (zh) * | 2017-12-28 | 2023-10-31 | 上海细胞治疗研究院 | 自表达cd47抗体的间皮素特异性car-t细胞及其用途 |
| CA3090791A1 (en) | 2018-02-11 | 2019-08-15 | Memorial Sloan-Kettering Cancer Center | Non-hla restricted t cell receptors and uses thereof |
| JP2021514360A (ja) * | 2018-02-23 | 2021-06-10 | カーサリクス プロプライエタリー リミテッド | Ｔａｇ−７２を標的化するｔ細胞疾患処置 |
| GB201804701D0 (en) * | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
| GB201807945D0 (en) * | 2018-05-16 | 2018-06-27 | Ospedale San Raffaele Srl | Vector production |
| WO2019232477A2 (en) * | 2018-05-31 | 2019-12-05 | Washington University | Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies |
| BR112020025764A2 (pt) | 2018-06-19 | 2021-05-11 | Biontech Us Inc. | neoantígenos e usos dos mesmos |
| US12281152B2 (en) | 2018-08-01 | 2025-04-22 | City Of Hope | TAG72 targeted chimeric antigen receptor modified T cells for treatment of TAG72-positive tumors |
| EP3982979A4 (en) * | 2019-06-12 | 2023-10-18 | The Regents Of The University Of California | READY-TO-USE GENETICALLY MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF |
| US20230000915A1 (en) * | 2019-11-25 | 2023-01-05 | Kyoto University | T-cell master cell bank |
| JP7699154B2 (ja) * | 2020-05-22 | 2025-06-26 | 重▲慶▼精准生物技▲術▼有限公司 | 腫瘍微小環境を逆転させる融合タンパク質及びその使用 |
| EP4161536A4 (en) | 2020-06-04 | 2024-08-14 | Carisma Therapeutics Inc. | Novel constructs for chimeric antigen receptors |
| WO2022061837A1 (en) * | 2020-09-27 | 2022-03-31 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Fibronectin extra domain b (edb) -specific car-t for cancer |
| EP4251741A1 (en) | 2020-11-30 | 2023-10-04 | CRISPR Therapeutics AG | Gene-edited natural killer cells |
| US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| EP4320224A1 (en) * | 2021-04-07 | 2024-02-14 | Century Therapeutics, Inc. | Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells |
| WO2023110824A1 (en) * | 2021-12-15 | 2023-06-22 | Novo Nordisk A/S | Novel integrin associated protein (iap) |
| CN114573710A (zh) * | 2022-02-16 | 2022-06-03 | 南方医科大学珠江医院 | 一种靶向抗原同时外泌cd47抗体的免疫细胞及其应用 |
| WO2024036214A2 (en) * | 2022-08-10 | 2024-02-15 | Jasper Therapeutics, Inc. | Modified stem cell compositions and methods for use |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| WO1998018809A1 (en) * | 1996-10-25 | 1998-05-07 | Cell Genesys, Inc. | Targeted cytolysis of cancer cells |
| US6908763B1 (en) | 1997-08-22 | 2005-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian common lymphoid progenitor cell |
| US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| US6761883B2 (en) | 1999-06-29 | 2004-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian myeloid progenitor cell subsets |
| ATE373421T1 (de) | 1999-06-29 | 2007-10-15 | Univ Leland Stanford Junior | Untereinheiten von myeloid-progenitorzellen von säugern |
| AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| DE10130800B4 (de) | 2001-06-22 | 2005-06-23 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität |
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7592174B2 (en) | 2002-05-31 | 2009-09-22 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation of mesenchymal stem cells |
| WO2003102215A2 (en) | 2002-05-31 | 2003-12-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of identifying and isolating stem cells and cancer stem cells |
| US7494807B2 (en) | 2002-09-13 | 2009-02-24 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian megakaryocyte progenitor cell |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2005021594A2 (en) * | 2003-08-29 | 2005-03-10 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use |
| JPWO2005035586A1 (ja) * | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| US7816088B2 (en) | 2003-12-05 | 2010-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Identification, isolation and elimination of cancer stem cells |
| WO2005123909A2 (en) | 2004-06-09 | 2005-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and characterization of muscle regenerating cells |
| US7641897B2 (en) | 2004-11-23 | 2010-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Feeder layer and serum independent embryonic stem cells |
| WO2006089218A2 (en) | 2005-02-17 | 2006-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for modulating angiogenesis |
| WO2006116076A2 (en) * | 2005-04-28 | 2006-11-02 | Genencor International, Inc. | Tab molecules |
| US7514229B2 (en) | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| CA3163418A1 (en) | 2006-10-06 | 2008-05-22 | Jeffrey S. Isenberg | Prevention of tissue ischemia, related methods and compositions |
| WO2008073316A2 (en) | 2006-12-07 | 2008-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of acute myeloid leukemia stem cells |
| US7781179B2 (en) | 2006-12-07 | 2010-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of transitional cell carcinoma stem cells |
| US8765390B2 (en) | 2006-12-08 | 2014-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of squamous carcinoma stem cells |
| EP3722317B1 (en) | 2008-01-15 | 2024-08-07 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| JP5547656B2 (ja) | 2008-01-15 | 2014-07-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| DK2279253T3 (en) | 2008-04-09 | 2017-02-13 | Maxcyte Inc | Construction and application of therapeutic compositions of freshly isolated cells |
| US8320687B2 (en) | 2009-02-05 | 2012-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Universal lossy compression methods |
| US8741648B2 (en) * | 2009-06-05 | 2014-06-03 | Cellular Dynamics International, Inc. | Reprogramming T cells and hematopoietic cells |
| KR101962476B1 (ko) | 2009-07-03 | 2019-03-26 | 아비펩 피티와이 리미티트 | 면역성 접합체 및 그 제조방법 |
| CA3057650A1 (en) | 2009-09-15 | 2011-03-24 | Irving L. Weissman | Synergistic anti-cd47 therapy for hematologic cancers |
| WO2011041453A1 (en) | 2009-09-29 | 2011-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
| WO2011094538A1 (en) | 2010-01-29 | 2011-08-04 | The Board Of Trustees Of The Leland Stanford Junior University | Depletion of teratoma-forming pluripotent stem cells |
| DK2569013T3 (da) | 2010-05-14 | 2017-02-13 | Univ Leland Stanford Junior | Humaniserede og kimære monoklonale antistoffer til cd47 |
| US9212229B2 (en) * | 2010-09-08 | 2015-12-15 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EA201391059A1 (ru) | 2011-01-18 | 2014-05-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Композиции для лечения рака и способы их применения |
| AU2012236068A1 (en) * | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| AU2013222267A1 (en) | 2012-02-22 | 2014-07-31 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer |
| EA201990959A1 (ru) | 2012-04-11 | 2020-02-10 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| ES2941370T3 (es) | 2012-07-13 | 2023-05-22 | Univ Pennsylvania | Control de la toxicidad para la actividad antitumoral de los CAR |
| US9765156B2 (en) | 2012-07-13 | 2017-09-19 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
| US9045734B2 (en) | 2012-07-31 | 2015-06-02 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and characterization of progenitor cells from mesothelium |
| CA2890438C (en) | 2012-11-13 | 2022-10-18 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| HK1216647A1 (zh) | 2012-12-12 | 2016-11-25 | Vasculox Inc. | 治疗性cd47抗体 |
| ES2831315T3 (es) * | 2013-04-03 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | Generación efectiva de células T dirigidas al tumor derivadas de células madre pluripotentes |
| KR20160079854A (ko) * | 2013-10-31 | 2016-07-06 | 프레드 헛친슨 켄서 리서치 센터 | 변형된 조혈 줄기/선조 및 비-t 효과기 세포 및 이의 용도 |
| US10323077B2 (en) * | 2014-02-10 | 2019-06-18 | Emory University | Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer |
| US20180214527A1 (en) * | 2015-03-26 | 2018-08-02 | City Of Hope | Bi-specific targeted chimeric antigen receptor t cells |
| CN108368520B (zh) * | 2015-11-04 | 2023-01-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| CN105331586B (zh) * | 2015-11-20 | 2020-09-15 | 上海细胞治疗研究院 | 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途 |
-
2016
- 2016-11-23 ES ES20169645T patent/ES2988976T3/es active Active
- 2016-11-23 SG SG11201803493UA patent/SG11201803493UA/en unknown
- 2016-11-23 CN CN202211541314.3A patent/CN116121281B/zh active Active
- 2016-11-23 ES ES16867445T patent/ES2862907T3/es active Active
- 2016-11-23 CA CA3004120A patent/CA3004120A1/en active Pending
- 2016-11-23 MY MYPI2018701648A patent/MY189819A/en unknown
- 2016-11-23 IL IL296410A patent/IL296410A/en unknown
- 2016-11-23 AU AU2016361451A patent/AU2016361451B2/en active Active
- 2016-11-23 JP JP2018546725A patent/JP6976960B2/ja active Active
- 2016-11-23 EP EP16867445.5A patent/EP3380117B1/en active Active
- 2016-11-23 WO PCT/AU2016/051141 patent/WO2017088012A1/en not_active Ceased
- 2016-11-23 EP EP20169648.1A patent/EP3708588A1/en active Pending
- 2016-11-23 CN CN201680069543.6A patent/CN109152824B/zh active Active
- 2016-11-23 SG SG10201912825XA patent/SG10201912825XA/en unknown
- 2016-11-23 US US15/778,836 patent/US11400145B2/en active Active
- 2016-11-23 EP EP20169645.7A patent/EP3708587B1/en active Active
-
2018
- 2018-05-24 IL IL259586A patent/IL259586B2/en unknown
-
2021
- 2021-11-10 JP JP2021183110A patent/JP2022027762A/ja active Pending
-
2022
- 2022-06-09 US US17/836,052 patent/US20220305106A1/en not_active Abandoned
-
2024
- 2024-01-08 AU AU2024200108A patent/AU2024200108A1/en active Pending
- 2024-01-26 JP JP2024010098A patent/JP2024028648A/ja active Pending
-
2025
- 2025-07-17 US US19/271,861 patent/US20250340612A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535701A5 (enExample) | ||
| JP2020533958A5 (enExample) | ||
| JP2017524367A5 (enExample) | ||
| JP2020517295A5 (enExample) | ||
| JP2021500881A5 (enExample) | ||
| JP2021137024A5 (enExample) | ||
| FI3703750T3 (fi) | B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja | |
| CA3158025C (en) | Anti-bcma chimeric antigen receptors | |
| JP2016520074A5 (enExample) | ||
| JP2023552998A (ja) | 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用 | |
| KR20230095083A (ko) | Cd7 표적의 키메라 항원 수용체 및 이의 용도 | |
| JP2018532407A5 (enExample) | ||
| WO2012079000A4 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
| RU2020100865A (ru) | Лечение рака с помощью гуманизированного анти-cd19 химерного антигенного рецептора | |
| JP2018527014A5 (enExample) | ||
| US11773384B2 (en) | Chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells | |
| JPWO2020061498A5 (enExample) | ||
| US20220133792A1 (en) | Signaling platforms for chimeric antigen receptor t cells | |
| EP4273175A1 (en) | Novel chimeric antigen receptor and use thereof | |
| EP4194472A1 (en) | Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof | |
| CA3194577A1 (en) | Methods for triggering safety killing mechanisms using a cd47-sirp.alpha. blockade agent | |
| JPWO2020228824A5 (enExample) | ||
| JPWO2022151851A5 (enExample) | ||
| IL304857A (en) | Preparations and methods for treating HER2 POSITIVE cancer | |
| RU2019107136A (ru) | Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор |